Revisiting antiangiogenic therapy to target prostate cancer metabolism
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210188
- Recipient
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $249,999
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Houston, TX 77030, USA
Award details come from USAspending.gov.
About this award
The Department of the Army Medical Command awarded a $249,999 Project Grant to The University of Texas M.D. Anderson Cancer Center through the Military Medical Research and Development program. This three-year grant will fund research from September 2022 to August 2025 to revisit antiangiogenic therapy and target prostate cancer metabolism.
The Military Medical Research and Development program, designated by CFDA #12.420, supports basic, applied, and advanced biomedical research with the goals of improving military and public health outcomes. This award will advance those goals by investigating medical solutions applicable to service members and the public through innovative research into targeting prostate cancer metabolism after antiangiogenic treatment. The University of Texas M.D. Anderson Cancer Center will leverage its expertise in oncology to deliver targeted research services under this federal grant.
Quick answers
Who received award W81XWH2210188?
W81XWH2210188 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by Medical Command (Department of the Army) on September 1, 2022.
How much is award W81XWH2210188 worth?
$249,999 has been obligated on W81XWH2210188.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award